ReviewRadiation and environmental biophysics2025
Contributions of the radonorm project to European and international radiation protection research.
Review in Radiation and environmental biophysics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
RadoNorm has come a long way since its inception, in addressing and managing risks for radon and NORM. The output of the project has been substantial in generating new findings and developing novel methodologies and tools. At the same time, the project has been translating its results into recommendations, which have been published as deliverables and scientific publications, and communicated to various stakeholders through its annual meetings, monthly webinars and the most recent RadoNorm Showcase Meeting held in Brussels. This review aims to produce a comprehensive summary of RadoNorm results and recommendations until this point (June 2025) as well as the recent discussions at the RadoNorm Showcase Meeting in March 2025, where the results were presented to a variety of stakeholders including the radiation research platforms. The results are presented under the themes of "health effects and risks", "exposure and mitigation" and "risk communication and societal aspects". RadoNorm has performed a comprehensive assessment of what has been achieved and what future questions have arisen from the latest results of the project, which are also elaborated upon herein and addressed as challenges for the European radiation research platforms to assimilate into their research portfolios.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.